The next focusIR Investor Webinar takes places on 14th May with guest speakers from WS Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksPoolbeg Pharma Share News (POLB)

Share Price Information for Poolbeg Pharma (POLB)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 13.75
Bid: 13.60
Ask: 13.90
Change: 0.15 (1.10%)
Spread: 0.30 (2.206%)
Open: 13.60
High: 13.75
Low: 13.75
Prev. Close: 13.60
POLB Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

TRADING UPDATES: Katoro Gold launches fundraising, eyes board shake-up

Mon, 12th Feb 2024 19:44

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Monday and not separately reported by Alliance News:

----------

Metals One PLC - Finland and Norway-focused developer of brownfield metals projects - Reports results from eight diamond drillholes at the R1 Hook target, located within the Rauta 9-11 licence area at the Black Schist Project in Finland. Says significant intersections of mineralised black schists were identified in all eight drill holes, whilst drilling has also demonstrated geological continuity with the company's existing Resource at R1 which could support future resource expansion.

----------

Beacon Energy PLC - Isle of Man-registered oil and gas company - Provides operational update on the Schwarzbach-2 well in the Erfelden field. Reports the sand jetting operation with a coiled tubing unit has now been completed. Expects to recommence production in the coming days following reinstallation of the rod pump. States the impact of the sand jetting will only be known once production has been restored and a stabilised and sustained flow rate from the rod pump has been achieved, at which time the company will provide an update. Once the well has been fully cleaned up following the sand jetting operations, it is expected that the rod pump will be replaced with an electrical submersible pump to maximise production - this is currently scheduled to take place in April 2024.

----------

Baron Oil PLC - London-based oil and gas exploration and appraisal company - Updates on operational activities on the TL-SO-19-16 production sharing contract, offshore Democratic Republic of Timor-Leste. Notes Baron's wholly owned subsidiary, SundaGas Banda Unipessoal Lda, has entered into contracts to conduct a survey at the planned drilling location for the Chuditch-2 appraisal well. Site survey operations are expected to be carried out at the location during February and early March 2024. Explains the objective of the site survey is principally to identify any potential hazards at the proposed well site, ensuring that a drilling rig can be safely located there with minimal environmental impact.

----------

Star Energy Group PLC - onshore energy company - Announces updated competent persons report for its conventional oil and gas interests. Reports proven reserves net present value of USD143 million at December 31, little changed from USD144 million in 2021. Says total of proven and probable reserves was USD235 million at December 31, rising from USD215 million in 2021.

----------

Poolbeg Pharma PLC - London-based clinical-stage biopharmaceutical company targeting diseases with a high unmet medical need - Says independent research conducted on behalf of Poolbeg confirms a more than USD10 billion market opportunity for POLB 001 in cancer immunotherapy-induced cytokine release syndrome as an orally delivered preventative therapy. Believes rare and orphan diseases represent a significant value creation opportunity. Sees a substantial opportunity for medicines to treat these severe and often chronic conditions. Anticipates that acquiring and commercialising rare and orphan drugs could potentially lead to attractive revenue generation opportunities.

----------

Kromek Group PLC - Sedgefield, England-based detection technology supplier - Agrees to allot new shares to another two loan note holders in consideration of them cancelling their loan notes that were due to expire later this month. This follows loan note conversion announced last Monday. The two further loan note holders will cancel their loan notes, which total GBP1.2 million, including accrued interest. Kromek agrees to allot around 16.5 million shares in consideration of the cancellation at 7.5 pence per share. The cancellation is subject to shareholder approval.

----------

Katoro Gold PLC - London-based gold and nickel exploration and development company - Raises GBP750,000 via broker-led placing and subscription with new and existing shareholders to support business development at 0.1 pence per share. Plans changes to board to maximise value from existing interests and to secure new cost-effective opportunities globally, with a focus on critical metals including uranium. Appoints strategic consultant, Paul Johnson, former chief executive of Power Metal Resources PLC and Metal Tiger PLC, to assist the board with a reinvigoration of the business model, business operations, strategic direction and enhanced communications with investors. Plans name change to Katoro Global Resources PLC.

----------

Enteq Technologies PLC - Ascot, England-based energy services technology and equipment supplier - Provides an update on the progress of the SABER Tool technology. Expects to receive USD100,000 in the first half of financial 2025 from contract win.

----------

Silverwood Brands PLC - holding company established to invest primarily in branded consumer businesses - Says VSA Capital Ltd has transferred around 2.3 million shares to Chief Executive Andrew Gerrie in settlement of a legal dispute. Following this transfer, finalises arrangements for the proposed cancellation of the 228 million shares issued in connection with the acquisition of a 20% stake in Lush Cosmetics Ltd and Lush Cosmetic Warriors.

----------

Athelney Trust PLC - invests in smaller UK companies for dividend and capital growth - Reports net asset value at December 31 was 209.1 pence, down 4.7% from 219.4p the year before. Recommends final dividend of 7.6p, making a total payout of 9.8p, increased from 9.6p, a rise of 2.0%. NAV total return was negative 4.4% compared to negative 26.2% the year before. Describes the year as "disappointing". Notes the company suffered negative absolute returns and has underperformed compared to the FTSE 250 largely because of ongoing negative sentiment for UK smaller companies and comparatively high UK interest rates through the year. But, believes there is now a strong case for investment in UK equities....which "offer great value for money".

----------

RTW Biotech Opportunities Ltd - London-based venture capital firm focused on biotechnology companies - Notes Arix shareholders vote to place Arix Bioscience PLC into voluntary liquidation. Following this, the assets of Arix have been transferred to RTW in exchange for the issue of new ordinary shares in RTW Bio to eligible Arix shareholders. In November, RTW agreed to acquire the entirety of Arix's assets, with shareholders receiving 1.4633 RTW shares for each share in the company. RTW also provided a cash exit to Arix's largest shareholder, Acacia Research Corp, which has been given a total of USD57.1 million in exchange for its 26% stake in the company.

----------

By Jeremy Cutler, Alliance News reporter

Comments and questions to newsroom@alliancenews.com

Copyright 2024 Alliance News Ltd. All Rights Reserved.

More News
21 Dec 2022 19:20

TRADING UPDATES: Atlantis Japan underperforms; Bellevue lowers payout

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Wednesday and not separately reported by Alliance News:

Read more
21 Dec 2022 13:37

Poolbeg identifies new drug candidates with OneThree

(Sharecast News) - Biopharmaceutical company Poolbeg Pharma has successfully identified potential new drug candidates from its respiratory syncytial virus (RSV) artificial intelligence (AI) programme with OneThree Biotech, it announced on Wednesday.

Read more
14 Dec 2022 21:54

TRADING UPDATES: Poolbeg acquires license; Afentra expects PSA delay

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Wednesday and not separately reported by Alliance News:

Read more
14 Dec 2022 16:14

Poolbeg secures exclusive licence to possible obesity drug tech

(Sharecast News) - Infectious disease-focussed biopharmaceutical company Poolbeg Pharma has acquired an exclusive licence from AnaBio sister company InsuCaps, it announced on Wednesday, to use its patented microencapsulation and nanoencapsulation oral delivery technologies in metabolic syndrome-related diseases, including obesity, pre-diabetes and diabetes.

Read more
2 Dec 2022 19:33

TRADING UPDATES: Time Out eyes Riyadh; MTI Wireless wins deal

(Alliance News) - The following is a round-up of updates by London-listed companies, issued this week and not separately reported by Alliance News:

Read more
15 Nov 2022 17:25

Poolbeg Pharma wins funding for oral vaccine development

(Alliance News) - Poolbeg Pharma PLC on Tuesday said it has received funding from the Irish Government to improve the manufacturing, distribution and administration of its oral vaccines.

Read more
8 Nov 2022 13:06

Poolbeg announces 'breakthrough' in AI drug target programme

(Sharecast News) - Infectious disease pharmaceutical developer Poolbeg Pharma announced a "significant breakthrough" in its artificial intelligence (AI) programme with partner OneThree Biotech on Tuesday, through the discovery of novel drug targets for the treatment of respiratory syncytial virus (RSV).

Read more
8 Nov 2022 12:18

IN BRIEF: Poolbeg makes "significant breakthrough" in AI programme

Poolbeg Pharma PLC - London-based clinical stage infectious disease pharmaceutical company - Announces "significant breakthrough" in its artificial intelligence programme with its partner OneThree Biotech Inc, a New York-based drug discovery-focused firm. Says breakthrough is the discovery of novel drug targets for the treatment of respiratory syncytial virus. The identification of these targets allow for the final stages of the programme to start, Poolbeg explains. This will involve the identification of small molecule inhibitors to treat RSV infections. The team is "particularly excited", the firm says, as these include a range of targets for which there are known drugs with existing Phase I safety and tolerability data. Results are expected before the end of 2022.

Read more
4 Oct 2022 14:14

Poolbeg Pharma upbeat on US patent application progress

(Sharecast News) - Infectious disease pharmaceutical company Poolbeg Pharma updated the market on its intellectual property (IP) position around 'POLB 001' on Tuesday, which it described as a small molecule immunomodulator for the treatment of severe influenza.

Read more
4 Oct 2022 10:14

Poolbeg expects formal patent grant soon to treat hypercytokinemia

(Alliance News) - Poolbeg Pharma PLC on Tuesday said that the US Patent & Trademarks Office has indicated that its patent application concerning the use of POLB 001 and its homologues for the treatment of hypercytokinemia is allowable.

Read more
4 Oct 2022 08:46

LONDON MARKET OPEN: Stocks rise as market sentiment recovers

(Alliance News) - Stock prices in London opened sharply higher on Tuesday, lifted by more positive market sentiment following the UK government's tax U-turn, as well as some positive trading updates.

Read more
4 Oct 2022 07:52

LONDON BRIEFING: Pound, oil, gold up; Truss vows fiscal responsibility

(Alliance News) - Stocks in London are called higher on Tuesday, as the market watches closely for further clues regarding the UK's economic direction.

Read more
27 Sep 2022 06:59

IN BRIEF: Poolbeg Pharma teams up for Melioidosis vaccine

Poolbeg Pharma PLC - London-based pharmaceutical company - On Wednesday reported it a signed an in-license agreement for the development of a Melioidosis vaccine candidate with University College Dublin. Melioidosis is an infectious disease spread by a bacterium in contaminated soil or water. It has a minimum fatality rate of around 10% and no vaccine for the disease exists. Poolbeg's late preclinical stage vaccine candidate has the name POLB 003. It is being developed following several years of research.

Read more
21 Sep 2022 16:18

Poolbeg inks exclusive deal for melioidosis vaccine candidate

(Sharecast News) - Clinical-stage infectious disease pharmaceutical company Poolbeg Pharma has signed an exclusive licence agreement with University College Dublin (UCD), it announced on Wednesday, for a late preclinical-stage vaccine candidate for melioidosis.

Read more
6 Sep 2022 14:04

IN BRIEF: Poolbeg shares rises on narrowed loss, strong pipeline

Poolbeg Pharma PLC - London-based pharmaceutical company - In the six months ended June 30, narrows its pretax loss to GBP1.7 million from GBP2.3 million loss the year prior. Does not post a revenue figure, unchanged from the previous year. Research & development expenses rise to GBP657,000 from GBP414,000. Notes "significant" progress on POLB 001, its treatment for severe influenza. Expects outputs from its respiratory syncytial virus and influenza artificial intelligence programmes by the end of 2022 and the second quarter of 2023, respectively. Adds it has "strong financial resources available to progress its products and platforms."

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.